Aneta Rogalska

Has grant

associate professor/PhD, DSc

Lodz University of Technology

Poland

Research Interests

Explore related searches

Professors in Poland Professors in Cancer Biology Cancer Biology professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Aneta Rogalska is an Associate Professor at the University of Lodz, Poland. Her research focuses on the molecular mechanisms of cancer treatment, particularly in the context of ovarian cancer and the efficacy of PARP inhibitors. Recent articles authored by Dr. Rogalska explore the roles of oxidative stress, targeted drug delivery strategies, and the intricacies of resistance mechanisms in BRCA1/2 mutated cancer models.

Recent Grants

Grant: Close

Wykorzystanie olaparibu i inhibitorów kinazy ATR/CHK1 jako celowanej terapii przeciwnowotworowej opartej na syntetycznej letalności

Open Date: 2020-07-01

Close Date: 2024-06-01

Grant: Close

Autofagia w terapii raka jajnika-ciemna czy jasna strona epotilonów?

Open Date: 2018-01-01

Close Date: 2018-12-01

Grant: Close

Indukcja apoptozy przez epotilon B i analog doksorubicyny WP 631 w komórkach raka jajnika wrażliwych i opornych na leki przeciwnowotworowe

Open Date: 2010-01-01

Close Date: 2013-01-01

Articles (18)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (12)

Natalia Sanz del Olmo

KTH Royal Institute of Technology

SWEDEN

View details

Izabela Szymczak-Pajor

Medical University of Lodz

POLAND

View details

Piotr Krzeczyński

Chief Specialist

Łukasiewicz Research Network - Industrial Chemistry Institute

POLAND

View details

Agnieszka Sliwinska

Head/ Associate Professor

Medical University of Lodz

POLAND

View details

Agnieszka Marczak

University of Łódź

POLAND

View details

Maksim Ionov

Professor

Lodz University of Technology

POLAND

View details

Damian Kołat

Medical University of Lodz

POLAND

View details

Udo Gaipl

Head of Radiation Immunobiology

Universitätsklinikum Erlangen

GERMANY

View details

Dorota Rybaczek

Associate Professor

Lodz University of Technology

POLAND

View details

Aleksandra Szwed-Georgiou

University of Łódź

POLAND

View details

Jiří Smejkal

Assistant professor

Jan Evangelista Purkyně University in Ústí nad Labem

CZECH REPUBLIC

View details

Michal Mikula

Professor

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aneta Rogalska

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (18)

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models

MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model

Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in TP53-Mutated Epithelial Ovarian Cancer Cell Lines

Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer

Uncovering miRNA–mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors

Evaluation of the role of oxidative stress in the anticancer effects of CHK1 and PARP-1 inhibitors in HepG2 cells

Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?

Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival

Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells

The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCAMUT and BRCAWT Ovarian Cancer Cells

Newly Synthesized Melphalan Analogs Induce DNA Damage and Mitotic Catastrophe in Hematological Malignant Cancer Cells

Synthesis and In Vitro Activity of Novel Melphalan Analogs in Hematological Malignancy Cells

PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway

Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines

Current Implications of microRNAs in Genome Stability and Stress Responses of Ovarian Cancer

Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches

Ruthenium Dendrimers against Human Lymphoblastic Leukemia 1301 Cells

PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness

Collaborators (12)

Natalia Sanz del Olmo

Izabela Szymczak-Pajor

Piotr Krzeczyński

Agnieszka Sliwinska

Agnieszka Marczak

Maksim Ionov

Damian Kołat

Udo Gaipl

Dorota Rybaczek

Aleksandra Szwed-Georgiou

Jiří Smejkal

Michal Mikula

Make your next move.